Onasemnogen abeparvovec (1) – Itvisma®
5q-associated spinal muscular atrophy with ≥ 4 copies of the SMN2 gene and SMA type 2, type 3, type 4 or of undefined type, aged ≥ 2 years
Characteristics
| Start date | 01.08.2026 |
|---|---|
| Resolution | 21.01.2027 – active procedure |
| INN | Onasemnogen abeparvovec |
| Brand name | Itvisma® |
| Pharm. company | Novartis Pharma GmbH |
| G-BA Procedure ID | D-1353 |
| Therapeutic area | Nervous system diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions